Using E.coli To Identify Stability Liabilities in Therapeutic and Disease-Causing Proteins
Many years have passed since recombinant human insulin, the first medicine made via recombinant DNA technology, was approved by the FDA. The continuous rise in the approval of protein therapeutics demonstrates the potential that biopharmaceuticals have to become the medicines of the future.
This exclusive Technology Networks webinar focuses on the most recent and innovative strategies for therapeutic antibody development and production. Your speaker, Professor Brockwell, will describe the development and use of a new assay to investigate important proteins in disease screening and the biopharmaceutical industry.
Attend this webinar to:
- Hear more about monoclonal antibodies and their impact
- Discover incredible studies and recent developments in this field
- Follow the development of a new assay used to investigate important proteins in biopharma